Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line treatment. Although much is known about the pleiotrop...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI AG
2020-02-01
|
| Serier: | Cells |
| Fag: | |
| Online adgang: | https://www.mdpi.com/2073-4409/9/2/378 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|